Hungarian Radiology

[Advisory Meeting of the European radiographers]


JUNE 20, 2006

Hungarian Radiology - 2006;80(03-04)



Further articles in this publication

Hungarian Radiology

[Renal cystic lesions The importance of CT in diagnosis and management in correlation with Bosniak classification]

AL-ABSI Mohammed, QAIS Abdulmalik, AL-NONO Ibrahim, GHILAN Abdulilah, GAFOUR Abdul Mohammed

[OBJECTIVE - The purpose of this study was to assess the importance of CT in differentiating renal cystic masses of surgical causes from those of non-surgical masses. PATIENTS AND METHODS - The patients included in this study were collected from a private diagnostic center and university hospital prospectively, yielding a total of 55 analyzable renal cystic lesions. A careful helical CT abdomen focusing on the kidneys with intravenous contrast was obtained from all patients. The lesions were categorized into surgical and medical renal cystic masses using the Bosniak classification system supported by histology reports and follow up protocols for medical cases. RESULTS - Of 55 cases, 35 were classified as surgical (13 lesions as category IV and 22 as III) and 20 as medical cases (15 as category II and 5 as III). Out of 22 resected category III lesions 15 were found to be malignant and all categorized as type IV were malignant. No malignancies have been identified in the prospectively monitored group of patients. CONCLUSION - Our series results are comparable with other teaching institution series, and support the usefulness of the Bosniak classification system in separating renal cystic lesion into surgical and non-surgical lesions but with diagnostic categorization difficulty of complicated multilocular hydatid cysts versus neoplastic (category III) cystic masses.]

Hungarian Radiology

[Radiological diagnosis of lung cancer - 2005 Literature review Onco Update 2005]


[Our aim is to review the radiologic literature of lung cancer of 2004 and some remarkable publications from 2003. There are three main groups in the recent publications dealing with lung cancer’s radiology. The first group comprises those reviews and metaanalyses which focus on the overall utility and reliability of routinely applied modalities such as CT and MRI. In the second group we find original articles reporting on the experience with new modalities. This group is dominated by publications dealing with positron emission tomography and the first clinical results of combined PET-CT technology. In the third part we review those articles dealing with lung cancer screening. Radiological lung cancer screening is in the focus of interest again, mainly due to the introduction of low-dose CT which is undoubtadly the most sensitive radiological modality for the early detection of lesions, however, its clinical utility is debated. The papers referred are basically sceptic, but this is not the end, because controlled long term follow-up studies are still in progress. Part of the publications report on the first clinical results of new methods, while others give valuable additional data regarding the performance of “well established” radiological modalities.]

Hungarian Radiology

[Markusovszky memorial session]


Hungarian Radiology

[Scientific session on the 85th Anniversary of the Clinic of Radiology in Debrecen]


Hungarian Radiology

[Quality insurance in radiology]

FEHÉR Lászlóné

All articles in the issue

Related contents

Lege Artis Medicinae

[A short chronicle of three decades ]


[Hungarian professional periodicals started quite late in European context. Their publish­ing, editing and editorial philosophy were equally influenced by specific historical and political situations. Certain breaking points of history resulted in termina­tion of professional journals (War of In­de­pendence 1848-1849, First and Se­cond World Wars), however there were pe­riods, which instigated the progress of sciences and founding of new scientific journals. Both trends were apparent in years after the fall of former Hungarian regime in 1990. The structure of book and journal publishing has changed substantially, some publishers fell “victim” others started successfully as well. The latters include the then-established publishing house Literatura Medica and its own scientific journal, Lege Artis Me­di­cinae (according to its subtitle: New Hun­garian Medical Herald) issued first in 1990. Its appearance enhanced significantly the medical press market. Its scientific publications compete with articles of the well-established domestic medical journals however its philosophy set brand-new trends on the market. Concerning the medical community, it takes on its problems and provides a forum for them. These problems are emerging questions in health care, economy and prevention, in close interrelation with system of public health institutions, infrastructure and situation of those providing individual health services. In all of them, Lege Artis Medicinae follows consequently the ideas of traditional social medicine.]

Clinical Neuroscience

[Health status and costs of ambulatory patients with multiple sclerosis in Hungary]

PÉNTEK Márta, GULÁCSI László, RÓZSA Csilla, SIMÓ Magdolna, ILJICSOV Anna, KOMOLY Sámuel, BRODSZKY Valentin

[Background and purpose - Data on disease burden of multiple sclerosis from Eastern-Central Europe are very limited. Our aim was to explore the quality of life, resource utilisation and costs of ambulating patients with multiple sclerosis in Hungary. Methods - Cross-sectional questionnaire survey was performed in two outpatient neurology centres in 2009. Clinical history, health care utilisation in the past 12 months were surveyed, the Expanded Disability Status Scale and the EQ-5D questionnaires were applied. Cost calculation was conducted from the societal perspective. Results - Sixty-eight patients (female 70.6%) aged 38.0 (SD 9.1) with disease duration of 7.8 (SD 6.7) years were involved. Fifty-five (80.9%) had relapsing-remitting form and 52 (76.5%) were taking immunomodulatory drug. The average scores were: Expanded Disability Status Scale 1.9 (SD 1.7), EQ-5D 0.67 (SD 0.28). Mean total cost amounted to 10 902 Euros/patient/year (direct medical 67%, direct nonmedical 13%, indirect costs 20%). Drugs, disability pension and informal care were the highest cost items. Costs of mild (Expanded Disability Status Scale 0-3.5) and moderate (Expanded Disability Status Scale 4.0-6.5) disease were 9 218 and 17 634 Euros/patient/year respectively (p<0.01), that is lower than results from Western European countries. Conclusion - Our study provides current inputs for policy making and contributes to understanding variation of costof- illness of multiple sclerosis in Europe.]

Clinical Neuroscience

[Account on the scientific meeting of Környey Society in 2010. Part 2.]

Clinical Neuroscience

The prevalence of sarcopenia and dynapenia according to stage among Alzheimer-type dementia patients

YAZAR Tamer, YAZAR Olgun Hülya

Aim - In this study, the aim was to identify the prevalence of sarcopenia and dynapenia according to disease stage among Alzheimer-type dementia (AD) patients and collect data to suggest precautions related to reducing the disease load. Method - The study was completed with 127 patients separated into stages according to Clinical Dementia Rating Scale (CDR) criteria and 279 healthy volunteers aged 18-39 years and 70-80 years abiding by the exclusion criteria who agreed to participate in the research. Our prospective and cross-sectional study applied the CDR and mini mental test (MMSE) to patients with disorder in more than one cognitive area and possible AD diagnosis according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association) diagnostic criteria. The patient and control groups had skeletal muscle mass index (SMMI), muscle strength and physical performance assessed with sarcopenia diagnosis according to European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria. Results - In our study, in parallel with the increase in disease stage of AD patients, the prevalence of sarcopenia (led by severe sarcopenia) and dynapenia was higher compared to a control group of similar age. Conclusion - In chronic, progressive diseases, like AD, identification of changes in parameters, like muscle mass and strength and reductions in physical performance in the early period, is important for identification and to take precautions in the initial stages considering the limitations of the preventive effects of treatment applied after diagnosis of AD.

Clinical Neuroscience

[Dopamine agonists in Parkinson’s disease therapy - 15 years of experience of the Neurological Clinics from Tîrgu Mureș. A cross-sectional study ]

SZÁSZ József Attila, CONSTANTIN Viorelia, MIHÁLY István, BIRÓ István, PÉTER Csongor, ORBÁN-KIS Károly, SZATMÁRI Szabolcs

[Background and purpose - There is relatively few data regarding the usage of dopaminagonists for the treatment of Parkinson’s disease; furthermore, there are no publications regarding Central- and Eastern-European countries. The aim of the study was to evaluate the use of dopamine agonists as a therapeutic option amongst Parkinson’s disease patients admitted to the Neurological Clinics of Tîrgu Mures during the last 15 years. Methods - In our study we investigated the data of all Parkinson’s patients treated at our clinics between the 1st of January 2003 and the 31st of December 2017. We analyzed the particularities of dopamine agonists’ usage based on the therapeutic recommendations from the final report of these patients. Regarding time since the diagnosis, we divided the patients in two groups: less than or equal to 5 years and more than 5 years. Results - During the studied period a total of 2379 patients with Parkinson’s disease were treated at the Clinics. From the 1237 patients with disease duration under 5 years 665 received dopamine agonists: 120 as monotherapy, 83 together with monoamine oxidase inhibitors and in 234 cases associated with levodopa. The remaining 228 patients were treated with a triple combination of levodopa, dopamine agonists and monoamine oxidase inhibitors. In patients suffering from Parkinson’s disease for more than 5 years, in 364 cases out of 653 a dopamine agonist was part of the therapy. Conclusion - The usage of dopamine agonists was similar to the data presented in other studies. We consider that clinicians treating the disease should, with the necessary prudence, use the available and recommended dopamine agonist with the utmost courage to their maximum therapeutic potential.]